Ionis Pharmaceuticals stock fell 2.23% despite Roche's Phase 3 kidney trial showing a 43.1% proteinuria reduction, with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results